Patent Yard Sign in
Expired, full termArchive

Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor

US 6,485,964 B1 · Assignee: Arris Pharmaceutical Corporation · Inventors: Wu; Hong et al.

USPTO PDF

Overview

The published document from the USPTO: abstract, claims, description and drawings. Open it full size

Read the whole patent

Listed from its USPTO record in Patent Yard's full-term archive. Its claims, description and drawings are in the USPTO PDF and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed April 15, 1997. A US utility patent lasts 20 years from filing, so its term ended April 15, 2017.
  • Patents filed before May 29, 2000 can't get a term adjustment for USPTO delays, and any other extension is capped at five years, so it can't still be in force.
  • We haven't checked its US family, and a later related patent could still be in force. We check US rights only.
FiledApril 15, 1997
GrantedNovember 26, 2002
Term endedApril 15, 2017
Application number08/839605
Classification (CPC)A01K67/0276 +2 more
Length16 pages

Timeline

Timeline From USPTO dates

1998200020022004200620082010201220142016Application filedApril 15, 1997Patent grantedNov 26, 2002Term endedApril 15, 2017

Sources & verification